Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648617 | 0.78 | MAPT (0.37) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL11992937 | 0.78 | MAPT (0.37) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL7759337 | 0.76 | MAPT (0.36) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL14416578 | 0.76 | MAPT (0.39) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL4266617 | 0.76 | CYP3A4 (0.37) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL4274331 | 0.76 | MAPT (0.42) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL19167947 | 0.76 | MAPT (0.39) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL1537019 | 0.74 | CTSD (0.32) | CTSD | |
| SCHEMBL14416576 | 0.73 | MAPT (0.37) | MAPTALOX15CYP3A4ESR1ESR2 | |
| SCHEMBL10067412 | 0.73 | TRPA1 (0.38) | MAPTALOX15CYP3A4ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10920230-B2 | Methylotrophs for aquaculture and animal feed | KNIPBIO, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2017133675-A1 | METHOD FOR PREPARING HIGH-PURITY CYCLOHEXENONE LONG-CHAIN ALCOHOL | 大鹏药品工业株式会社 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017125087-A1 | MANUFACTURING METHOD FOR HIGH-PURITY CYCLOHEXENONE LONG-CHAIN ALCOHOL | 大鹏药品工业株式会社 | 2017-07-27 | — | — | WO | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011032936-A1 | NITROOXYESTERS, THEIR PREPARATION AND USE | DSM IP ASSETS B.V. (NL) | 2011-03-24 | — | — | WO | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-5427905-A | Thermally processable image-recording material including reductone developing agent | POLAROID CORPORATION (US) | 1995-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | MAPT 1278/4885ALOX15 599/4885CYP3A4 493/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | MAPT 1639/4885ALOX15 585/4885CYP3A4 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.